33. Consolidated companies as of 31 December 2022
Name of the subsidiary |
Country |
% voting right Galapagos NV |
Change in % voting |
|---|---|---|---|
AboundBio Inc. |
United States |
100% |
100% |
CellPoint B.V. |
The Netherlands |
100% |
100% |
Galapagos Biopharma Belgium BV |
Belgium |
100% |
|
Galapagos Biopharma Netherlands B.V. |
The Netherlands |
100% |
|
Galapagos Biopharma Spain S.L.U. |
Spain |
100% |
|
Galapagos Biopharma Italy S.r.l. |
Italy |
100% |
|
Galapagos Biopharma Germany GmbH |
Germany |
100% |
|
Galapagos Biopharma Sweden AB |
Sweden |
100% |
|
Galapagos Biopharma Norway AS |
Norway |
100% |
|
Galapagos Biopharma Finland Oy |
Finland |
100% |
|
Galapagos Biopharma Denmark ApS |
Denmark |
100% |
|
Galapagos Biopharma Austria GmbH |
Austria |
100% |
|
Galapagos Biopharma Ireland Ltd |
Ireland |
100% |
|
Galapagos Biotech Ltd |
United Kingdom |
100% |
|
Galapagos B.V. |
The Netherlands |
100% |
|
Galapagos GmbH |
Switzerland |
100% |
|
Galapagos, Inc. |
United States |
100% |
|
Galapagos NV |
Belgium |
Parent company |
|
Galapagos Real Estate Belgium BV |
Belgium |
100% |
|
Galapagos Real Estate Netherlands B.V. |
The Netherlands |
100% |
|
Galapagos SASU |
France |
100% |
|
Xenometrix, Inc. in liquidation |
United States |
100% |
|
In 2022, we acquired all of the issued and outstanding shares in CellPoint and AboundBio.
There are no significant restrictions on the group’s ability to access or use assets, or settle liabilities, of one of the group’s subsidiaries.